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Abstract 
Background: 8-Aminoquinolines such as primaquine clear mature Plasmodium falciparum gametocytes that are 
responsible for transmission from human to mosquitoes and bring radical cure in Plasmodium vivax by clearing 
dormant liver stages. Deployment of primaquine is thus of relevance for malaria elimination efforts but challenged by 
the widespread prevalence of glucose-6-phosphate dehydrogenase deficiency (G6PDd) in endemic countries since 
primaquine in G6PDd individuals may lead to acute haemolysis. In this study, the prevalence of G6PDd was investi-
gated in different settings in Ethiopia using phenotyping and genotyping approaches.
Methods: Community and school based cross-sectional surveys were conducted from October to December 2016 
in four administrative regions (Gambela, Benishangul Gumuz, Oromia, and Amhara) in Ethiopia. Finger prick blood 
samples were collected for G6PD enzyme activity using the CareStart™ G6PD screening test and genotyping of 36 
selected single nucleotide polymorphisms (SNPs) located in the G6PD gene and its flanking regions.
Results: Overall, the prevalence of phenotypic G6PDd was 1.4% (22/1609). For the first time in the Ethiopian popula-
tion, the African variant (A−) was detected in 3.5% (7/199) of the limited set of genotyped samples, which were all 
phenotypically normal. Interestingly, all of these individuals had a variation at the rs2515904 locus. Strong geographi-
cal variation was observed for both phenotypic and genotypic G6PDd; three-quarters of the phenotypically G6PDd 
individuals were detected in Gambela.
Conclusion: A very low prevalence of G6PDd was detected in the present study populations. The presence of the 
A− variant alongside other G6PD mutants and the patchy distribution of G6PDd indicate that larger studies specifi-
cally designed to unravel the distribution of G6PDd at small geographical scale may be needed to tailor malaria 
elimination efforts in Ethiopia to the local context.
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Background
The substantial reduction in the global burden of 
malaria in the last 15  years prompted a renewed inter-
est in malaria elimination [1]. Vector control interven-
tions and case management with effective anti-malarials 
remain the cornerstones in the fight against malaria [2]. 
Current antimalarial drugs primarily target the blood 
stage asexual parasites that are uniquely associated with 
the signs and symptoms of the disease; with incomplete 
activity against mature Plasmodium falciparum gameto-
cytes (sexual stages) that are responsible for human-to-
mosquito transmission [3] and the dormant liver stages 
(hypnozoites) in Plasmodium vivax that are responsible 
for multiple relapses weeks or months after the primary 
infections have resolved [4]. Transmission reduction 
for both P. vivax and P. falciparum [5] and radical cure 
in P. vivax [6] are integral parts of the effort to eliminate 
malaria. Elimination efforts require drugs that not only 
alleviate symptoms, but also prevent transmission and 
provide a radical cure [7].
Primaquine (PQ), an 8-aminoquinoline, is the only 
licensed drug to date that can clear circulating mature 
gametocytes and the hypnozoites of P. vivax [8, 9]. How-
ever, utilization of PQ is hindered by the association of 
glucose-6-phosphate dehydrogenase deficiency (G6PDd) 
and PQ-induced haemolysis [10–12]. The human G6PD 
gene, located on the X-chromosome [13], codes for a 
cytosolic enzyme [14] with key roles to produce the 
reducing equivalent nicotinamide adenine dinucleotide 
phosphate (NADPH) that is required to protect cells, 
including red blood cells (RBCs), from oxidizing agents 
[15]. The G6PD gene has multiple mutant alleles which 
entail a decrease in enzyme activity; expressing the G6PD 
deficient (G6PDd) phenotype [16]. In humans, G6PDd 
is the most common enzyme defect [17] that affects 
close to 400 million people worldwide [18]. More than 
200 different mutations or combinations of mutations 
that are responsible for gradients of clinical conditions 
have been identified. The G6PDd variants may remain 
asymptomatic in the absence of triggers but may result 
in haemolytic anaemia induced by medications, infec-
tion, or ingestion of certain foods due to oxidative stress. 
Any person with RBC G6PD activity < 30% of the nor-
mal adjusted male median enzyme activity is considered 
G6PDd while > 80% is considered normal [19]. Strong 
regional patterns in the distribution of variants have been 
reported [20]. The Mediterranean variant (rs5030868) 
exhibits exceedingly low residual enzyme activity (< 1%) 
[21] while the Asian variants are more diverse [22] and 
could cause adverse effects (5–32% residual activity) 
[23]. The common G6PD allelic variants in sub-Saharan 
Africa are the wild type G6PD*B, G6PD*A+ (a non-
deficient variant, A376G), and G6PD*A− (the deficient 
variant, A376G plus G202A) [16, 17]. G6PD*A− vari-
ants with substitutions at G542T, G680T or T968C were 
also identified [24, 25]. Compared to the Mediterranean 
(rs5030868) and South East Asian variants, the Afri-
can variant is generally considered to result in a milder 
degree of deficiency and less severe haemolysis [20]; 
although incidents of life-threatening haemolysis have 
been reported for G6PD A− [26].
Recent estimates indicated that the number of new 
cases and deaths attributable to malaria in Ethiopia 
declined by 96.5% and 88.7%, respectively, between 
1990 and 2015 [27]. Unlike most of Africa, P. vivax is 
uniquely highly prevalent in the country. Ethiopia con-
tributed towards 10% of the global vivax malaria cases in 
2016 [28]. Ethiopia set an ambitious plan of eliminating 
malaria from selected low-endemic districts by 2020 [29]. 
The World Health Organization (WHO) recommends 
single low dose PQ as a P. falciparum gametocytocide 
and a 14-days course for radical cure of P. vivax [30]. PQ, 
which was used in the country for over a quarter of a cen-
tury before it was removed from treatment regimens for 
no documented reasons in 1990 [31], is currently rein-
corporated into the treatment policy of Ethiopia in elimi-
nation settings. However, very little evidence is available 
on the distribution of G6PDd in Ethiopia and the asso-
ciated mutations. With the move to deploy PQ widely it 
is timely and important to generate evidence on G6PDd 
in the Ethiopian population. In this study, G6PDd was 
investigated in different malaria endemic settings in the 
Ethiopian population using enzymatic assay and multiple 
allelic forms of G6PD were analysed by genotyping.
Methods
Study sites and population
Community and school based cross-sectional sur-
veys were conducted from October to December 2016 
to investigate G6PDd by phenotyping and genotyp-
ing approaches in Ethiopia. Nine Woredas (admin-
istrative unit equivalent to district) representing 
different malaria endemic settings were selected from 
four Regional States (Gambela, Benishangul Gumuz, 
Oromia and Amhara Regions). Community based 
cross-sectional surveys were conducted in Abobo 
and Lare Woredas of Gambela, Meng and Mao-komo 
Woredas of Benishangul Gumuz, Gomma and Adama 
Woredas of Oromia Regional States, Fig. 1. Community 
mobilization was conducted prior to the study. Resi-
dents who were willing to participate in the study were 
requested to come to the study clinic the next day to 
donate finger prick blood samples. School based sur-
veys were conducted in Amhara Regional State in Jawi 
(Jawi general primary school), North Achefer (Ahuri 
primary school), and Bahir Dar Zuria (Andassa primary 
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school) Woredas, Fig.  1. School based surveys were 
conducted to estimate parasite prevalence [32] and per-
formed as routinely done using methods developed by 
Brooker and colleagues to obtain an age-balanced set of 
samples [33].
Blood sample collection and G6PD phenotypic screening
Socio-demographic data were recorded using a pre-
tested questionnaire and individuals were requested to 
donate a finger prick blood sample (~ 300 µl) that was 
used for the assessment of activity of the G6PD enzyme 
using the CareStart™ G6PDd screening test (Access 
Bio, Inc., New Jersey, USA). The remaining blood was 
used to prepare dried blood spots (DBS) on What-
Mann 3MM (Whatman, Maidstone, UK) filter papers 
[32]. DBS samples were air dried, individually packed 
in a cardboard that had the study code and stored in 
zip-locked plastic bags containing self-indicating silica 
gel desiccant beads (Geejay Chemicals Ltd) and trans-
ported to the laboratory at AHRI and stored at − 20 °C 
freezer until processed.
DNA extraction and single nucleotide polymorphism (SNP) 
genotyping
Genomic DNA was extracted using saponin-chelex dual 
extraction procedure as described previously [34] from a 
6 mm diameter punch that was eluted in 150 µl of a 6% 
Chelex in DNase/RNase free water solution and stored at 
− 20 °C until further use. Thirty-six SNPs located in the 
G6PD gene and its flanking regions were selected from 
those identified in the literature and on public databases 
based on criteria described earlier [35–37]. Samples that 
were found deficient with the enzymatic assay (22) and a 
subset of 211 G6PD phenotypically normal samples, ran-
domly selected from all study sites, were genotyped using 
Kompetitive Allele Specific PCR (KASP™) (LGC Genom-
ics, UK). For the 36 putative SNP sequences identified, 
KASP assays were designed, comprising two allele-spe-
cific forward primers, and one common reverse primer 
(Additional file  1). Primer designs were using sequence 
derived from NCBI dbSNP and each sequence screened 
for potential surrounding polymorphism using popu-
lation information held [37]. Alternative primers were 
designed if another surrounding polymorphism had an 
Fig. 1 Map of study sites. Community surveys were conducted in Lare and Abobo Woredas of Gambela Regional State, Meng (in Banieshegol, 
Keshaf and Belmeguha Kebeles) and Maokomo (in Yeamesera, Tulu, Taja and Gure Kebeles) Woredas of Benishangul-Gumuz Regional State, Goma 
(in Limmu Sapa, Limmu Shaye, Cocee and Chedero Suse Kebeles) and Adama (Batu Degaga Kebele) Woredas of Oromia Regional State. School 
surveys were conducted in South Achefer (Yinessa and Yeboden Kebeles), Bahir Dar Zuria (Andassa Kebele), and Jawi Woredas in Amhara Regional 
State. Elevation of each site (meters above sea level, m.a.s.l) is indicated in brackets
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alternative allele frequency greater than 1% (Additional 
file 2). If was not possible to avoid, then ambiguities were 
incorporated into the primer in order to minimize any 
potential impact on assay performance. Genotyping reac-
tions were performed in duplicate using the IntelliQube 
(LGC, Douglas Scientific, USA) to complete all sample 
DNA arraying, reagent dispensing, plate sealing and fluo-
rescence detection steps for SNP genotyping as described 
in detail before [37].
Data analysis
Questionnaire data was checked for completeness and 
double-entered along with all laboratory results in Red-
Cap (Vanderbilt University, USA) [38]. Statistical analysis 
was conducted using STATA 13 (StataCorp, TX, USA) 
and Graph Pad Prism 5.0 (Graph Pad Software Inc., CA, 
USA). Computation of Linkage Disequilibrium (LD) and 
haplotype analysis was done using Haploview version 4.2 
Software as stated elsewhere [39]. As a quality control, 
SNPs with greater than 10% missing genotype calls and 
more than 2% of male genotype calls that were (falsely) 
called heterozygous were excluded from analysis includ-
ing individuals with greater than 20% of the SNP data 
missing (Additional files 1 and 3). Monomorphic SNPs 
and those with less than 1% frequency were also excluded 
from LD and haplotype analysis. No sample size calcula-
tions were performed prior to data collection; 95% con-
fidence intervals (CI) were presented for all prevalence 
estimates.
Results
A total of 1609 individuals with a median age of 14 years 
(interquartile range [IQR]: 10–30); of whom 46.3% 
(745/1609) were females, participated in this study. The 
overall phenotypic G6PDd detected by the CareStart™ 
G6PDd screening test was 1.4% (95% confidence interval 
[CI] 1.0–2.1), with considerable variation between study 
sites. Of the 22 G6PDd individuals 16 were from Gamb-
ela Regional State: 6.6% (95% CI 3.5–11.0) of participants 
from Abobo and 1.5% (95% CI 0.3–4.4) of participants 
from Lare Woredas (Table 1). Of the phenotypically defi-
cient individuals 9 were females.
A total of 14 SNPs that did not meet the quality con-
trol were excluded from further analysis (Additional 
files 1 and 3): 1 SNP with > 10% missing genotype calls 
(rs35228794) and 13 SNPs with more than 2% of male 
genotype calls that were (falsely) called heterozygous 
(rs766420, rs915941, rs915942, rs1894260, rs2515906, 
rs1050757, rs2230037, b36_153426256, rs4898389, 
rs5986877, rs7879049, rs7053878, rs2004651). Addition-
ally, 28 individuals with more than 20% missing calls were 
also excluded. Out of the 22 high quality G6PD SNPs, 6 
were found monomorphic [including the well-known 
variants in Africa rs76723693 (968T>C); rs5030872 
(542A>T); rs137852328 (680) and the Mediterranean 
variant (rs5030868)]. One SNP (rs12389569) had < 1% 
minor allele frequency (MAF) (Table  2). Thus, further 
analyses focused on 15 SNPs that passed the quality con-
trol. Four of these SNPs are located in the G6PD gene (2 
synonymous and 2 missense variants) and the other in 
flanking regions of the gene; i.e. 3 immediately down-
stream of G6PD gene and the remaining were intergenic 
(1), intron (5), non-coding exon (2) and 5′ UTR variants 
(1).
Among the common SNPs genotyped, the A376G 
mutation was detected in 34 individuals (17.1%, 95% CI 
12.1–23.0) (Tables  1 and 2); 9 (8.1%, 95% CI 3.8–14.8) 
hemizygous males, 7 (8.0%, 95% CI 3.3–15.9) homozy-
gous females, and 18 (20.7%, 95% CI 12.7–30.7) heterozy-
gous females. In three male participants, a heterozygous 
signal was observed and confirmed upon repeating the 
assay. The G202A mutation was detected in 7 (3.5%, 95% 
CI 1.4–7.1) individuals of whom 4 (3.6%, 95% CI 1.0–9.0) 
were hemizygous males and the remaining (3.4%, 95% CI 
0.7–9.6) were heterozygous females. All G202A hemizy-
gous males were hemizygous for the A376G mutation 
and of the G202A heterozygous females 2 were homozy-
gous and 1 was heterozygous for the A376G mutation. 
The African variant was not detected among the pheno-
typically deficient individuals, only one male phenotypi-
cally deficient individual had hemizygous A376G variant. 
That same individual was hemizygous for rs28470352, 
rs5986990, rs762515, rs111827785, and rs60030796 vari-
ants. The remaining phenotypically deficient individuals 
had wild type variants for all the SNPs analyzed in this 
study. Taken together, all individuals that carried the 
G202A variant also carried the A376G mutations and the 
A− African variant could not explain the phenotypic var-
iation observed in the present study. All individuals with 
the A− variant (male hemizygotes and female heterozy-
gotes) were found carrying a variation at the rs2515904 
locus (4.6%, 95% CI 2.1–8.5). Like the African variant, 
the variation at the rs2515904 locus was detected only in 
phenotypically normal individuals, Table  2. In a similar 
fashion to the geographic distribution of the phenotypic 
G6PDd, 4/7 (57.1%) of the A− variants were detected 
from Adama; they were detected from two families each 
and two of them were brothers (Table  1). The G202A 
variant showed high geographic clustering, whereas the 
A376G mutation was uniformly distributed across all 
study sites.
Linkage disequilibrium (LD) plot could be constructed 
only for the whole population. It was not stratified based 
on gender, ethnicity and study setting due to small sam-
ples genotyped. One LD block was constructed that con-
sisted of rs28470352, rs73573478, rs5986990, rs1050829 
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(376), rs762515, rs113492957, rs111827785, and 
rs60030796 (Fig.  2). Pairwise LD was high in this study 
(combined gender result was median 1.00; range 0.64–
1.00). Generated haplotypes were listed in Table 3.
Discussion
A very low frequency (1.4%, 22/1609) of phenotypically 
evident G6PDd was detected in this study. For the first 
time in published literature, the African variant (A−) was 
detected in an Ethiopian population. Of the genotyped 
samples 3.5% (7/199) were A− variants (4 hemizygous 
males and 3 homozygous females) and consisted of both 
the G202A and the A376G mutations. Three quarters of 
the phenotypically deficient individuals were from one 
Region, Gambela. None of the phenotypically deficient 
individuals were found to have the A− variant. Uniquely, 
all individuals with the A− variant were found carry-
ing a variation at the rs2515904 locus that was previ-
ously found in perfect LD with the A− variant and was 
reported protective against clinical malaria [40–42].
The high prevalence of G6PDd detected by the phe-
notypic assay in Gambela Region is in line with a recent 
finding of 7.3% phenotypic deficiency in the same region 
[43] and with an earlier finding (of 4.0%) among tribes 
in Eritrea [44]. According to the 2015 National Malaria 
Indicator Survey, Gambela Region reported the highest 
Table 2 Single nucleotide polymorphisms detected in the study population
SNP single nucleotide polymorphism
The following SNPs were monomorphic and excluded from further analysis: rs5030869, rs76723693 (968), rs137852328 (680), rs5030868, rs5030872 (542), and 
rs137852318. *SNP with minor allele frequency < 1% and was omitted from further analysis. Italicized are the well-known rs1050828 (G202A) and rs1050828 (A376G) 
African polymorphisms. Bolded and italicized (rs2515904) indicates a SNP that was detected in individuals who carried the 376 and 202 variants
Reference SNP 
identifier
Chromosome 
position
SNP frequency by sex, proportion deficient 
(n/N)
Total SNP frequency, 
proportion deficient (n/N)
Ancestral: 
alternate 
allele
Function
Male 
hemizygotes
Female 
homozygotes
Female 
heterozygotes
Hemizygous/
homozygous
Heterozygous
rs28470352 153,753,490 8.3 (10/121) 5.8 (5/87) 20.7 (18/87) 5.8 (12/208) 10.1 (21/208) T:A Intergenic 
variant
rs61042368 153,755,336 5.0 (6/120) 1.2 (1/86) 1.2 (1/86) 2.4 (5/206) 1.5 (3/206) G:A Downstream 
gene vari-
ant
rs12389569 153,757,734 0 (0/120) 0 (0/85)* 2.4 (2/85) 0 (0/205) 1.0 (2/205) G:A Downstream 
gene vari-
ant
b36_153413623 153,760,429 1.7 (2/121) 2.4 (2/85) 3.5 (3/85) 1.9 (4/206) 1.5 (3/206) G:A Synonymous 
variant
rs2230036 153,760,953 5.9 (7/119) 1.2 (1/86) 1.2 (1/86) 2.4 (5/205) 2.0 (4/205) C:T Synonymous 
variant
rs73573478 153,761,564 8.9 (11/123) 2.2 (2/90) 4.4 (4/90) 4.7 (10/213) 3.3 (7/213) G:A Non coding 
exon vari-
ant
rs5986990 153,761,628 7.8 (9/115) 5.9 (5/85) 21.2 (18/85) 6.0 (12/200) 10.0 (20/200) G:A Non coding 
exon vari-
ant
rs2515905 153,762,075 3.3 (4/120) 1.2 (1/87) 4.6 (4/87) 2.4 (5/207) 1.9 (4/207) G:A Intron variant
rs2515904 153,762,771 3.3 (4/121) 1.2 (1/87) 4.6 (4/87) 2.4 (5/208) 1.9 (4/208) G:C Intron vari-
ant
rs1050829 153,763,492 8.3 (10/121) 7.9 (7/89) 20.2 (18/89) 6.7 (14/210) 10.0 (21/210) A:G Missense 
variant
rs1050828 153,764,217 3.3 (4/120) 0 (0/90) 3.3 (3/90) 1.9 (4/210) 1.4 (3/210) G:A Missense 
variant
rs762515 153,764,528 7.7 (9/117) 5.8 (5/86) 20.0 (17/86) 5.9 (12/203) 9.4 (19/203) T:C Intron variant
rs762516 153,764,663 3.3 (4/121) 1.2 (1/87) 4.6 (4/87) 2.4 (5/208) 1.9 (4/208) C:T Intron variant
rs113492957 153,773,062 9.2 (11/120) 2.3 (2/86) 3.5 (3/86) 4.9 (10/206) 2.9 (6/206) C:T Intron variant
rs111827785 153,775,785 18.2 (22/121) 9.6 (8/83) 24.1 (20/83) 12.8 (26/204) 11.8 (24/204) T:C 5′ UTR 
rs60030796 153,836,171 5.0 (6/119) 4.6 (4/87) 12.6 (11/87) 3.4 (7/206) 6.8 (14/206) A:G Downstream 
gene vari-
ant
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prevalence of malaria in Ethiopia (18.4% by RDT com-
pared to 0.1% country wide prevalence) [45] and it is one 
of the areas in the country with historically stable malaria 
transmission [46–48]. This might be attributable to its 
location within the humid tropical region of the country 
(< 500  masl), settlement and land-use changes [46], and 
periodic flooding [49]. The geographic overlap of the 
high malaria and G6PDd observed in this study is sup-
portive of the long-standing claim that this mutation was 
naturally selected by malaria [50].
Phenotypically evident deficiencies detected in 
G6PDd individuals often have matched genetic back-
ground (often of point mutation or haplotypes). A to G 
Fig. 2 Linkage disequilibrium (LD) plot estimated by Haploview. The numbers in the diamonds are D′ values, with red and no numbers 
representing a D′ value of 1 for the corresponding pair of variants. Strong LD is indicated by dark gray, whereas light gray and white indicate 
uninformative and low confidence values, respectively. LD blocks were created with the default algorithm in Haploview that creates 95% 
confidence bounds on D′ considered to be in strong LD, where 95% of the comparisons made are informative
Table 3 Haplotype frequencies in  phenotypically normal 
participants
SNPs refer to the following corresponding to Table 2: rs28470352, rs73573478, 
rs5986990, rs1050829 (376), rs762515, rs113492957, rs111827785, rs60030796. 
376 are bolded
Haplotypes Haplotype 
frequencies
TGG ATCTA 0.812
AGA GCCCG 0.076
TAG ATTCA 0.056
AGA GCCCA 0.045
TGG ATCCA 0.011
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substitution mutation at the rs1050829 locus (also known 
as A376G, exon 5) is associated with reduced production 
of G6PD enzyme that causes a milder variant, G6PD A+, 
resulting in 80% residual enzyme activity compared to 
normal values [51]. The G6PD deficient genotype A− is 
typically defined by the possession of both the rs1050829 
(A376G) allele and G to A substitution at the rs1050828 
locus (also known as G202A, exon 4). Type A− muta-
tions cause on average 12% residual G6PD activity [51]. 
Type A− is predominantly found in people who have 
African ancestry (and referred to as the African vari-
ant). In line with the hypothesis that the mutation lead-
ing to the African variant (G202A) might have arisen on 
a chromosome that carried the silent mutation (A376G), 
all G202A mutations in the present study were detected 
in individuals carrying the A376G mutation. Most of 
the phenotypically G6PD deficient individuals in the 
present study had no SNPs detected in the G6PD gene. 
There was one phenotypically deficient individual who 
had the A376G, together with variations at rs28470352, 
rs5986990, rs762515, rs111827785, and rs60030796 loci, 
but not the G202A. All other SNPs tested in this study 
were monomorphic for phenotypically deficient indi-
viduals, which might be explained by G6PD mutations 
in the Ethiopian population that were not tested in the 
present study [52, 53]. A relevant shortcoming of the cur-
rent study was that selected populations of G6PDd and 
G6PD normal individuals were included in the genotyp-
ing assays; the unavailability of an unbiased population 
makes it challenging to derive meaningful allele frequen-
cies. An additional major limitation was that the sample 
size was too small to estimate the frequencies of pheno-
typic G6PDd and mutations in the G6PD gene, as well as 
their associations with RDT performance with precision. 
The very small sample size, especially with the genotyp-
ing analysis, could also have contributed to the observed 
geographic clustering. The detection of the African vari-
ant of G6PDd in the present study and the predominant 
geographic pattern of patchy distribution of G6PDd 
underline the need for larger studies to have complete 
picture of the nationwide distribution of the deficiency to 
help build a resilient programmatic approach in the move 
towards eliminating malaria in Ethiopia.
With the limited number of genotyped samples from 
different study sites, 3.5% (7/199) of genotyped samples 
were of the A− variant. This contrasts with, previous 
studies conducted in different settings in Southwest Ethi-
opia, South Omo [34] and Jimma [52] that did not detect 
the African A− variant among their Ethiopian popula-
tions. One of the unique differences may lie in the study 
population; the previous studies were all done on clinical 
patients [52]; possibly missing variants that infer protec-
tion from clinical malaria. The other possible explanation 
is that these studies only included single settings, pos-
sibly missing the strong regional patterns in the distri-
bution of G6PD variants [20] and differences in ethnic 
background [43, 54, 55] as demonstrated in the present 
study. Apart from this the results from this study on the 
A376G variants (17.1%, 34/199) are in line with a recent 
finding from Jimma (23.3%) [52]. The Mediterranean 
variant (rs5030868, C563T) was not detected in any of 
these studies, including the present study [34, 52]. Allelic 
heterogeneity, the phenomenon in which different muta-
tions at the same locus cause the same phenotype, might 
have contributed to the discrepancy reported in previ-
ous studies as most of them relied on restriction diges-
tion [34]. Allelic variations can arise as a result of natural 
selection processes, exogenous mutagens, genetic drift, 
or genetic migration.
Mutations of G6PD can cause varying degrees of 
G6PDd and thus severity of haemolysis may vary. The 
patterns of oxidative haemolysis are well characterized 
in hemizygous males and homozygous females; whereas, 
heterozygous females may exhibit symptoms to varying 
degrees due to random inactivation of X-chromosomes 
[56]. The expression of G6PDd differs markedly among 
female heterozygotes as their RBC populations are vari-
able mosaics of deficient and normal cells [57] and can 
potentially be misclassified by currently available phe-
notypic diagnostic approaches. Although rapid tests that 
can be used at point-of-care were recently introduced for 
the diagnosis of G6PDd [58, 59], they may fail to accu-
rately identify individuals with intermediate deficiency 
(30–80% normal enzymatic activity, mainly heterozygote 
females) [19]. Heterozygous females who test normal 
or not deficient in qualitative G6PD screening tests can 
still experience substantial hemolysis [56]. A quantita-
tive technique is thus required to detect the intermediate 
levels of G6PD activity but this is not yet available as a 
point-of-care test and will have cost and logistics impli-
cations to overcome when developed and scaled-up [60, 
61].
A single low dose PQ as a gametocytocide in P. falci-
parum malaria and a 14-day course for radical cure in 
P. vivax is recommended by the WHO and this is being 
incorporated into country treatment policies. Most P. 
vivax malaria-endemic countries recommend PQ treat-
ment without prior G6PD testing [62]. The WHO malaria 
treatment guidelines address the 14-day course for pre-
venting relapse with caution, including a statement that 
good practice requires that the G6PD status of patients 
should be ascertained prior to administration of PQ [19]. 
On top of costs associated with deployment of G6PDd 
diagnostic tests, the largest challenge is the lack of stand-
ardized point-of-care diagnostic tests to-date to mitigate 
the risk of haemolysis associated with drugs like PQ. 
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Alternative strategies need to be explored in the Ethio-
pian settings where the frequency of G6PDd is very low 
and varies substantially between sites; blanket deploy-
ment of diagnostic tests might not be cost-effective. 
Strategies such as directly observed treatment (DOT), 
close medical supervision for potential PQ-induced 
haemolysis, as in tuberculosis care [63], using its exten-
sive health extension workers program (with counseling 
on how to recognize symptoms and signs of haemolytic 
anaemia) or approaches tailored to local context con-
sidering the varying geographic distribution of the defi-
ciency could be plausible options.
Conclusion
Prevalence of G6PDd is generally very low and varies 
substantially between settings in Ethiopia. The country 
could potentially benefit from tailored deployment of 
8-aminoquinolines like PQ. This study supports the evi-
dence that the incorporation of PQ into national treat-
ment guidelines for P. falciparum malaria would likely 
pose little risk to the population due to the very low gen-
otypic and phenotypic prevalence of G6PDd. Despite the 
low prevalence, alternative strategies including DOT or 
at least better screening for G6PDd, particularly among 
females, who are likely to be phenotypically normal by 
Carestart G6PD screening test, but may experience sub-
stantial haemolysis if they were genotypically female 
heterozygous, need to be considered to prevent P. vivax 
relapse.
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